Ascendiant Capital Markets Issues Pessimistic Forecast for Alzamend Neuro (NASDAQ:ALZN) Stock Price

Alzamend Neuro (NASDAQ:ALZN) had its price objective trimmed by Ascendiant Capital Markets from $35.00 to $32.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Alzamend Neuro Stock Performance

ALZN opened at $1.22 on Monday. The company’s 50-day simple moving average is $1.45 and its two-hundred day simple moving average is $2.63. Alzamend Neuro has a 52-week low of $1.06 and a 52-week high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.